Suzanne McGettigan, MSN, CRNP, AOCN
University of Pennsylvania Health System, Division of Hematology-Oncology, Perelman Center for Advanced Medicine, Philadelphia, PAAuthored Items
October 25, 2019 | November 2019 Vol 10, No 11
Twelve months of adjuvant oral dabrafenib + trametinib therapy significantly prolonged relapse-free survival versus placebo in patients with resected BRAF V600E/Kāmutant stage III melanoma.
Last modified: November 6, 2019